Big news! We’ve dosed the first patient in our Phase 2/3 GARDian3 trial for #Stargardtdisease (OCU410ST). With no approved treatment today, this huge milestone brings us one step closer to helping patients with this blindness disease. Details: bit.ly/4eWzm6n

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team $OCGN tinyurl.com/2dzpgr4w

Ocugen is accelerating progress in retinal disease with three BLAs on the horizon and welcome new experts to its Retina Scientific Advisory Board and Executive Leadership Team. Read more: bit.ly/4kVk6bb #GeneTherapy #BiotechLeadership

Our CSO Dr. Arun Upadhyay joins the #RARECast podcast to discuss Ocugen’s modifier #genetherapy and its potential to treat genetically diverse #retinaldiseases. He also co-authored a related study. 🔗 bit.ly/3GQBdwQ 📖 bit.ly/4f21Efu Global Genes IJMS MDPI

Inspired by voices like Molly Burke’s, we’re advancing science to potentially provide a gene therapy to all RP patients. Ocugen’s Phase 3 OCU400 liMeliGhT trial is currently enrolling. 📩 [email protected] 📞 484-237-3390 #OCU400 #RP #GeneTherapy #ClinicalTrials

$OCGN

Excited to attend #ASRS2025 in Long Beach! 🧬 Dr. Syed Shah on Gene Therapy for RP – Aug 1 🧬 Dr. Jay Chhablani on OCU410 – Aug 2 🧬 Dr. Ramiro Moldanado’s e-poster on OCU410ST More info 👉 asrs.org/annual-meeting #GeneTherapy #RetinaResearch #Biotech

🧬Ocugen will attend #WIO2025 in Amelia Island, FL! Dr. Majda Hadziahmetovic will present on OCU410 for geographic atrophy. Huma Qamar, MD, MPH, CMI will present on OCU410ST for Stargardt disease. Both on Aug 9 at 11 AM EST. Details: wioonline.org/upcoming-events #GeneTherapy #Ophthalmology

We're making bold strides in gene therapy for blindness. ✅ Promising OCU410 data ✅ Phase 3 OCU400 on track ✅ Dosing initiated for Phase 2/3 confirmatory trial for Stargardt ✅ Strategic partnership + OrthoCellix launch Read more: bit.ly/455W5bm #GeneTherapy #Biotech

An incredible day at #CGFlyIn! We joined 160+ advocates and collectively met with 105 Congressional offices to champion: ✅Give Kids a Chance Act ✅Accelerating Kids’ Access to Care ✅Access to breakthrough therapies Momentum is building! #GeneTherapy #RareDisease #Innovation

3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies Ocugen says it is on track to reshape the market for gene therapies against #eyedisorders over the next three years, including blindness-related diseases Ocugen #genetherapy #AAV hubs.li/Q03BybRm0

We are aiming for 3 BLAs in 3 years, a bold move toward advancing gene therapies for blindness diseases. Learn more about our vision in this Genetic Engineering & Biotechnology News feature. 🔗 bit.ly/4ofTzYW #Ocugen #GeneTherapy #Biotech

We're advancing gene therapies for retinal diseases like RP, Stargardt, and GA. With strong progress across our pipeline, we're on track for 3 BLAs in 3 years. Watch Dr. Musunuri's Chardan Conference update: bit.ly/4mvY1Bd #GeneTherapy #RareDisease #Innovation

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants $OCGN tinyurl.com/2ddtk4tr

August is #ChildrensEyeHealthandSafetyMonth! We're sharing vision tips from our clinical leaders. Today’s tip comes from Dr. Murthy Chavali, Ocugen’s Director of Clinical Development, who’s advancing gene therapies to help restore sight in patients with IRDs and AMD. #EyeHealth

In Authority Magazine Dr. Arun Upadhyay shares how Ocugen is challenging the status quo in biotech to create lasting impact for patients. Read more: bit.ly/4mwGWrr #BiotechInnovation #GeneTherapy #FutureOfMedicine

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease $OCGN tinyurl.com/23fb6gjy

EMA (EU Medicines Agency) gives Ocugen the green light to move forward with a single, U.S.-based Phase 2/3 trial for OCU410ST for MAA filing— bringing us closer to delivering the first treatment for Stargardt disease. Read: bit.ly/3V38bxi #GeneTherapy #RareDisease #Ocugen

In part one of our series, Molly Burke joins Dr. Lejla Vajzovic to discuss living with #retinitispigmentosa and the importance of patient perspectives in advancing research and treatment. Learn more: [email protected] | 484-237-3390 #GeneTherapy

In part two, Molly Burke talks with Dr. Lejla Vajzovic about how Ocugen’s Phase 3 LiMeliGhT clinical trial is providing hope to all RP patients—regardless of mutation or stage of the disease. Learn more: [email protected] | 484-237-3390 #RetinitisPigmentosa